KRAS and cancer: Elevated expression of CCT6A, RHOQ, and RRP12 was linked to lower survival rates, while high levels of UTP18, DDOST, YRDC, ACTG1, RFT1, and NLE1 correlated with improved survival outcomes.483 Chen et al. employed CRISPR/Cas9 to delineate the genetic interactions of chromatin regulatory factors (CRS) that influence drug responses in cancer, thus establishing a CRS gene interaction map to guide rational pharmacotherapy.484 Šuštić et al. identified ERN1 as a key modulator in the response of KRAS mutant colon cancer cells to MEK inhibitors.